Last Price$60.00.0%
Market Cap$2,336.7M
3Y Annual Expected Return
N/A
5Y Annual Expected Return
N/A
Annual EPS Growth
3Y: N/A
5Y: N/A
Shareholder Yield
0.0%
LTM P/E
Current: (30.6x)
5Y avg: (7.6x)
Stock quality
6/10
Good
LBPH Expected Return
3Y Annual Expected Return
5Y Annual Expected Return
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
LBPH vs Peer Set: Expected Return comparison
3Y Annual Expected Return
5Y Annual Expected Return
General
Expected Return
FINANCIAL METRICS
Company name
3Y Annual Expected Return
Revenue growth
EPS growth
Net Income margin
Longboard Pharmaceuticals, Inc.LBPH
N/A
N/A
(4.8%)
N/A
Median Peer Set
20.2%
14.8%
(19.3%)
7.5%
argenx SEARGX
39.4%
198.6%
(60.5%)
(24.1%)
Royalty Pharma plcRPRX
34.7%
(3.8%)
(43.7%)
37.9%
BeiGene, Ltd.BGNE
29.3%
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc.BMRN
24.9%
18.0%
139.3%
15.0%
United Therapeutics CorporationUTHR
21.8%
23.6%
25.7%
41.5%
Alnylam Pharmaceuticals, Inc.ALNY
18.7%
23.0%
(38.6%)
(12.4%)
Regeneron Pharmaceuticals, Inc.REGN
13.7%
8.3%
10.4%
31.1%
Vertex Pharmaceuticals IncorporatedVRTX
(4.6%)
11.7%
N/A
(4.9%)
BioNTech SEBNTX
(26.3%)
(77.4%)
(89.7%)
24.4%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
Explore more intrinsic value tools hub for LBPH
Earnings Power Value
Peter Lynch Fair Value
Discount rate
Intrinsic Value
Ben Graham Fair Value
Margin of safety
DCF value calculator
Reverse DCF
Relative Value
Peter Lynch charts
FAQ
What is Apple expected annual return?
Apple's expected annual return is approximately N/A for 3 years and N/A for 5 years.
What is Apple Earnings Growth?
As of Dec 13, 2024, Apple's 3Y Earnings Growth is approximately N/A.
What is Apple Shareholder Yield?
As of Dec 13, 2024, Apple's shareholder yield is approximately 0.0%.